Hims & Hers remains a 'Strong Buy' at $16, with fair value estimated at $22 despite recent headwinds. Click here to read an analysis of HIMS stock now.

Hims & Hers executives struck a confident tone about the company's growth prospects on Monday as it launches new specialties and expands rapidly into international markets. | Investors are concerned ...

HIMS fourth-quarter 2025 results are likely to benefit from new specialties and global expansion, but higher costs and GLP-1 ...

Hims & Hers Health is facing existential risk as regulatory uncertainty and margin erosion undermine its growth narrative. Click here to read why HIMS is a Sell.

Hims & Hers Health (HIMS) shares are higher today after the company revealed its $1.15 billion acquisition for Australian-based Eucalyptus ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

By Christy Santhosh Feb 19 (Reuters) - Hims & Hers Health said on Thursday it will acquire Australian digital health company ...

Telehealth company Hims & Hers Health (NYSE:HIMS) in Q4 CY2025, with sales up 28.4% year on year to $617.8 million. On the ...

Hims & Hers has agreed to acquire Australia-based Eucalyptus for up to $1.15 billion, expanding its international footprint ...

The company's full-year 2025 results showcased remarkable growth. Revenue surged to approximately $2.35 billion, representing a 59% increase compared to the prior year. Net income reached $128 million ...

Virtual care is steadily expanding as a mainstream healthcare channel, with Hims & Hers Health, Inc. HIMS and Teladoc Health, Inc. TDOC leveraging digital-first models to scale access. HIMS is a ...

Financial giants have made a conspicuous bullish move on Hims & Hers Health. Our analysis of options history for Hims & Hers Health (NYSE:HIMS) revealed 13 unusual trades. Delving into the details, we ...